Page 123 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 6 Overview of T-Cell Recognition 106.e1

MUL t IPL e -CH o IC e QU e S t I on S

1. How does the expression of human leukocyte antigen 3. How does cross-presentation differ from the classical pathway
(HLA)-DO most commonly modify the peptide repertoire of class I–restricted antigen presentation?
presented by major histocompatibility complex (MHC) class A. It involves exogenous antigens gaining access to MHC class
II molecules? I molecules.
A. It enhances presentation of most peptide epitopes. B. It utilizes the TAP (transporter associated with antigen
B. It targets MHC class II presentation to the correct endo- processing) transporter.
somal compartment. C. It involves degradation by the proteasome.
C. It inhibits peptide editing by HLA-DM. D. It uses only one subset of class I molecules for presentation.
D. It promotes release of the class II–associated invariant chain 4. What is the function of invariant chain in MHC class II
peptide (CLIP) fragment from MHC class II molecules.
biology?
2. How do the proteasome and immunoproteasome differ? A. It prevents class II acquisition of peptides made in the
A. They differ primarily in their subcellular localization. endoplasmic reticulum.
B. They differ with regard to targeting of ubiquitinated B. It targets class II molecules to endosomal compartments.
ligands. C. It helps degrade antigens internalized through the immu-
C. They differ in the number of subunits they contain. noglobulin receptor.
D. They differ in the sequence and structure of the β subunit. D. A and B